AU2005251913A1 - Pyrrolopyridine derivatives - Google Patents

Pyrrolopyridine derivatives Download PDF

Info

Publication number
AU2005251913A1
AU2005251913A1 AU2005251913A AU2005251913A AU2005251913A1 AU 2005251913 A1 AU2005251913 A1 AU 2005251913A1 AU 2005251913 A AU2005251913 A AU 2005251913A AU 2005251913 A AU2005251913 A AU 2005251913A AU 2005251913 A1 AU2005251913 A1 AU 2005251913A1
Authority
AU
Australia
Prior art keywords
methyl
pyrrolo
chloro
pyridin
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005251913A
Other languages
English (en)
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
Matthew Russell Johnson
William Leonard Mitchell
Alcide Perboni
Brian Peter Slingsby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412908A external-priority patent/GB0412908D0/en
Priority claimed from GB0424950A external-priority patent/GB0424950D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2005251913A1 publication Critical patent/AU2005251913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005251913A 2004-06-09 2005-06-07 Pyrrolopyridine derivatives Abandoned AU2005251913A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0412908A GB0412908D0 (en) 2004-06-09 2004-06-09 Compounds
GB0412908.6 2004-06-09
GB0424950.4 2004-11-11
GB0424950A GB0424950D0 (en) 2004-11-11 2004-11-11 Compounds
PCT/EP2005/006182 WO2005121140A1 (en) 2004-06-09 2005-06-07 Pyrrolopyridine derivatives

Publications (1)

Publication Number Publication Date
AU2005251913A1 true AU2005251913A1 (en) 2005-12-22

Family

ID=34969264

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005251913A Abandoned AU2005251913A1 (en) 2004-06-09 2005-06-07 Pyrrolopyridine derivatives

Country Status (25)

Country Link
US (1) US7589206B2 (enExample)
EP (1) EP1753764B1 (enExample)
JP (1) JP2008501758A (enExample)
KR (1) KR20070034049A (enExample)
AR (1) AR050158A1 (enExample)
AT (1) ATE412651T1 (enExample)
AU (1) AU2005251913A1 (enExample)
BR (1) BRPI0511874A (enExample)
CA (1) CA2569887A1 (enExample)
DE (1) DE602005010698D1 (enExample)
DK (1) DK1753764T3 (enExample)
ES (1) ES2317244T3 (enExample)
HR (1) HRP20090034T3 (enExample)
IL (1) IL179603A0 (enExample)
MA (1) MA28686B1 (enExample)
MX (1) MXPA06014471A (enExample)
NO (1) NO20070067L (enExample)
PE (1) PE20060430A1 (enExample)
PL (1) PL1753764T3 (enExample)
PT (1) PT1753764E (enExample)
RU (1) RU2006147278A (enExample)
SI (1) SI1753764T1 (enExample)
TW (1) TW200611695A (enExample)
UY (1) UY28945A1 (enExample)
WO (1) WO2005121140A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20060035A (sr) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
EP1787991B2 (en) * 2004-07-28 2020-06-24 Takeda Pharmaceutical Company Limited PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
KR100958830B1 (ko) * 2004-09-03 2010-05-24 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
EA200800562A1 (ru) * 2005-08-09 2008-06-30 Глаксо Груп Лимитед Производные имидазопиридина в качестве лигандов каннабиноидного рецептора
CA2643863A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008113818A1 (en) * 2007-03-21 2008-09-25 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2415765A4 (en) 2009-03-30 2012-08-15 Astellas Pharma Inc PYRIMIDINE COMPOUND
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
SI2599774T1 (sl) * 2010-07-29 2017-03-31 Astellas Pharma Inc. Zgoščene piridinske spojine kot CB2 kanabinoidni receptorski ligandi
EP2827846B1 (en) * 2012-03-19 2020-08-12 Sharon Anavi-Goffer Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists
MX355943B (es) 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
CA3120866A1 (en) * 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3379404D1 (en) * 1982-12-29 1989-04-20 Kureha Chemical Ind Co Ltd Cephalosporin derivatives
CA2031927A1 (en) 1989-12-27 1991-06-28 Imperial Oil Limited Method for improving the activity maintenance of a plasma initiator
FI922347A7 (fi) 1990-01-05 1992-05-22 Pfizer Atsaoksindolijohdannaiset
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
EP0745083B1 (en) 1994-02-18 1998-05-20 Boehringer Ingelheim Pharmaceuticals Inc. 2-HETEROARYL-5,11-DIHYDRO-6H-DIPYRIDO [3,2-b:2',3'-e][1,4]DIAZEPINES AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
JPH0920779A (ja) 1995-05-01 1997-01-21 Japan Tobacco Inc 縮合ヘテロ５員環アゼピン化合物類及びその医薬用途
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Ｍｃｐ―１アンタゴニストとしての２―フェニルベンズイミダゾール誘導体
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
ATE237023T1 (de) 1998-01-23 2003-04-15 Voith Paper Patent Gmbh Verfahren zur entfernung von feinen verunreinigungen aus einer faserstoffsuspension
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2342222A1 (en) 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
JP2002539124A (ja) 1999-03-10 2002-11-19 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
EP1165076A4 (en) 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS GONADOLIBERINE'S ANTAGONISTS
WO2000053180A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
JP2002538204A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
EP1171125A1 (en) 1999-03-10 2002-01-16 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
ES2238437T3 (es) 2000-04-28 2005-09-01 Acadia Pharmaceuticals Inc. Agonistas muscarinicos.
PL358877A1 (en) 2000-04-28 2004-08-23 Baxter Healthcare Sa 2-acyl indol derivatives and their use as anti-tumour agents
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ES2309088T3 (es) 2000-09-06 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Uso de pirazoles sustituidos para el tratamiento de alergias.
AU2001288714A1 (en) 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
JP2004510762A (ja) 2000-10-02 2004-04-08 メルク　エンド　カムパニー　インコーポレーテッド プレニル−蛋白質トランスフェラーゼの阻害剤
US6958358B2 (en) 2001-01-17 2005-10-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
HRP20030694A2 (en) 2001-02-02 2005-04-30 Bristol-Myers Squibb Company Composition and antiviral activity of substitutedazaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
IL158669A0 (en) 2001-05-14 2004-05-12 Bristol Myers Squibb Pharma Co Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
DE10143079A1 (de) 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
ES2278064T3 (es) 2001-10-19 2007-08-01 Transtech Pharma Inc. Derivados de beta-carbolina como inhibidores de ptp.
DE10152306A1 (de) 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
AU2003226724A1 (en) 2002-03-27 2003-10-08 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
ES2273077T3 (es) 2002-08-21 2007-05-01 Glaxo Group Limited Derivados de 2-fenilamino-4-trifluorometil-5 (bencil- o piridin-4-il-metil) carbamoilpirimidina como moduladores selectivos del receptor cannabinoide cb2.
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
TW200418830A (en) 2003-02-14 2004-10-01 Wyeth Corp Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate

Also Published As

Publication number Publication date
US7589206B2 (en) 2009-09-15
NO20070067L (no) 2007-02-09
PT1753764E (pt) 2009-01-28
IL179603A0 (en) 2007-05-15
JP2008501758A (ja) 2008-01-24
MXPA06014471A (es) 2007-03-21
ATE412651T1 (de) 2008-11-15
PE20060430A1 (es) 2006-05-25
DE602005010698D1 (de) 2008-12-11
ES2317244T3 (es) 2009-04-16
EP1753764B1 (en) 2008-10-29
EP1753764A1 (en) 2007-02-21
UY28945A1 (es) 2006-01-31
AR050158A1 (es) 2006-10-04
RU2006147278A (ru) 2008-07-20
CA2569887A1 (en) 2005-12-22
PL1753764T3 (pl) 2009-04-30
HRP20090034T3 (en) 2009-03-31
BRPI0511874A (pt) 2008-01-15
DK1753764T3 (da) 2009-02-16
TW200611695A (en) 2006-04-16
US20070219229A1 (en) 2007-09-20
KR20070034049A (ko) 2007-03-27
HK1104175A1 (en) 2008-01-04
SI1753764T1 (sl) 2009-02-28
WO2005121140A1 (en) 2005-12-22
MA28686B1 (fr) 2007-06-01

Similar Documents

Publication Publication Date Title
EP1753764B1 (en) Pyrrolopyridine derivatives
CN104039784B (zh) 取代的增环嘧啶及其用途
JP6432624B2 (ja) ３環性ヘテロ環化合物及びｊａｋ阻害剤
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
CN102015705B (zh) 稠合的杂环衍生物及其用途
EP2451813B1 (en) Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
CN102317287B (zh) 作为磷酸二酯酶抑制剂、用于治疗皮肤病的三唑并吡啶化合物
JP2003502272A (ja) 神経ペプチドｙ受容体拮抗薬としての二環式ピリジンおよびピリミジン誘導体
CN101679440A (zh) 作为jak3抑制剂的吡咯并嘧啶衍生物
WO2008116816A1 (en) Combination of cb2 ligand and paracetamol
CN103298817A (zh) 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
WO2007017264A2 (en) Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders
WO2008032764A1 (en) Fused heterocyclic derivative
WO2007088168A1 (en) Compounds
US20080221097A1 (en) Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
HK1104175B (en) Pyrrolopyridine derivatives
KR20150036763A (ko) 축환 복소환 화합물
TWI899220B (zh) 作為trpv4拮抗劑之嘧啶-4(3h)-酮衍生物
CN101001859A (zh) 吡咯并吡啶衍生物
CN101282973A (zh) 作为大麻素受体配体的咪唑并吡啶衍生物
HK40066114A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
HK40066114B (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
HK1170734A (en) Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application